دورية أكاديمية
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
| العنوان: | Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis. |
|---|---|
| المؤلفون: | MARRONE, A.1 (AUTHOR), ZAMPINO, R.1 (AUTHOR), KARAYANNIS, P.2 (AUTHOR), CIRILLO, G.3 (AUTHOR), CESARO, G.1 (AUTHOR), GUERRERA, B.1 (AUTHOR), RICCIOTTI, R.1 (AUTHOR), MIRAGLIA DEL GIUDICE, E.3 (AUTHOR), UTILI, R.4 (AUTHOR), ADINOLFI, L. E.1 (AUTHOR), RUGGIERO, G.1 (AUTHOR) |
| المصدر: | Alimentary Pharmacology & Therapeutics. Oct2005, Vol. 22 Issue 8, p707-714. 8p. 3 Charts. |
| مصطلحات موضوعية: | *HEPATITIS B virus, *DRUG resistance, *VIRUS inhibitors, *ANTIVIRAL agents, *LIVER diseases, *VIRAL hepatitis, *GENETIC mutation, *THERAPEUTICS |
| مستخلص: | Background : Drug-resistant mutants may emerge in patients with chronic hepatitis B receiving lamivudine therapy. Aim : To evaluate whether different viral mutational patterns may be associated with clinical reactivation during lamivudine treatment in patients with chronic B hepatitis. Methods : Eight anti-hepatitis B e-positive patients with (group A) and 14 patients without clinical exacerbation (five anti-hepatitis B e-positive, group B1; nine hepatitis B e antigen-positive, group B2) during lamivudine treatment were investigated. Results : ‘Polymerase region’: M204V/I variants were found in all group A patients, but in none of group B1 ( P = 0.0007) and in four of nine of group B2 (44%; P = 0.02) patients. The L180M substitution was detected in four of eight (50%) of group A and in none of groups B1 and B2. ‘Core promoter’: the double basic core promoter (A1762T/G1764A) variant was detected in seven of eight (87%) of group A and in one of five (20%; P = 0.03) of group B1 and one of nine (11%; P = 0.002) of group B2 patients. ‘Precore’: the G1896A stop codon mutation was present in seven of eight (87%) of group A and in zero of five ( P = 0.004) of group B1 and one of nine (11%; P = 0.002) of group B2. Conclusions : Different mutational patterns were observed in the lamivudine-treated patients with and without exacerbation. There was an association of the basic core promoter and stop codon mutations with lamivudine resistance in patients with disease exacerbation. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 18406395 1202 6 Academic Journal academicJournal 1202.35546875 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=18406395&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=02692813&ISBN=&volume=22&issue=8&date=20051015&spage=707&pages=707-714&title=Alimentary Pharmacology & Therapeutics&atitle=Clinical%20reactivation%20during%20lamivudine%20treatment%20correlates%20with%20mutations%20in%20the%20precore%2Fcore%20promoter%20and%20polymerase%20regions%20of%20hepatitis%20B%20virus%20in%20patients%20with%20anti-hepatitis%20B%20e-positive%20chronic%20hepatitis.&id=DOI:10.1111/j.1365-2036.2005.02653.x [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22MARRONE%2C+A%2E%22">MARRONE, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22ZAMPINO%2C+R%2E%22">ZAMPINO, R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22KARAYANNIS%2C+P%2E%22">KARAYANNIS, P.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22CIRILLO%2C+G%2E%22">CIRILLO, G.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22CESARO%2C+G%2E%22">CESARO, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22GUERRERA%2C+B%2E%22">GUERRERA, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22RICCIOTTI%2C+R%2E%22">RICCIOTTI, R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22MIRAGLIA+DEL+GIUDICE%2C+E%2E%22">MIRAGLIA DEL GIUDICE, E.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22UTILI%2C+R%2E%22">UTILI, R.</searchLink><relatesTo>4</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22ADINOLFI%2C+L%2E+E%2E%22">ADINOLFI, L. E.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22RUGGIERO%2C+G%2E%22">RUGGIERO, G.</searchLink><relatesTo>1</relatesTo> (AUTHOR) ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22Alimentary+Pharmacology+%26+Therapeutics%22">Alimentary Pharmacology & Therapeutics</searchLink>. Oct2005, Vol. 22 Issue 8, p707-714. 8p. 3 Charts. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22HEPATITIS+B+virus%22">HEPATITIS B virus</searchLink><br />*<searchLink fieldCode="DE" term="%22DRUG+resistance%22">DRUG resistance</searchLink><br />*<searchLink fieldCode="DE" term="%22VIRUS+inhibitors%22">VIRUS inhibitors</searchLink><br />*<searchLink fieldCode="DE" term="%22ANTIVIRAL+agents%22">ANTIVIRAL agents</searchLink><br />*<searchLink fieldCode="DE" term="%22LIVER+diseases%22">LIVER diseases</searchLink><br />*<searchLink fieldCode="DE" term="%22VIRAL+hepatitis%22">VIRAL hepatitis</searchLink><br />*<searchLink fieldCode="DE" term="%22GENETIC+mutation%22">GENETIC mutation</searchLink><br />*<searchLink fieldCode="DE" term="%22THERAPEUTICS%22">THERAPEUTICS</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Background : Drug-resistant mutants may emerge in patients with chronic hepatitis B receiving lamivudine therapy. Aim : To evaluate whether different viral mutational patterns may be associated with clinical reactivation during lamivudine treatment in patients with chronic B hepatitis. Methods : Eight anti-hepatitis B e-positive patients with (group A) and 14 patients without clinical exacerbation (five anti-hepatitis B e-positive, group B1; nine hepatitis B e antigen-positive, group B2) during lamivudine treatment were investigated. Results : ‘Polymerase region’: M204V/I variants were found in all group A patients, but in none of group B1 ( P = 0.0007) and in four of nine of group B2 (44%; P = 0.02) patients. The L180M substitution was detected in four of eight (50%) of group A and in none of groups B1 and B2. ‘Core promoter’: the double basic core promoter (A1762T/G1764A) variant was detected in seven of eight (87%) of group A and in one of five (20%; P = 0.03) of group B1 and one of nine (11%; P = 0.002) of group B2 patients. ‘Precore’: the G1896A stop codon mutation was present in seven of eight (87%) of group A and in zero of five ( P = 0.004) of group B1 and one of nine (11%; P = 0.002) of group B2. Conclusions : Different mutational patterns were observed in the lamivudine-treated patients with and without exacerbation. There was an association of the basic core promoter and stop codon mutations with lamivudine resistance in patients with disease exacerbation. [ABSTRACT FROM AUTHOR] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/j.1365-2036.2005.02653.x
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 8
[StartPage] => 707
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => HEPATITIS B virus
[Type] => general
)
[1] => Array
(
[SubjectFull] => DRUG resistance
[Type] => general
)
[2] => Array
(
[SubjectFull] => VIRUS inhibitors
[Type] => general
)
[3] => Array
(
[SubjectFull] => ANTIVIRAL agents
[Type] => general
)
[4] => Array
(
[SubjectFull] => LIVER diseases
[Type] => general
)
[5] => Array
(
[SubjectFull] => VIRAL hepatitis
[Type] => general
)
[6] => Array
(
[SubjectFull] => GENETIC mutation
[Type] => general
)
[7] => Array
(
[SubjectFull] => THERAPEUTICS
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => MARRONE, A.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => ZAMPINO, R.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => KARAYANNIS, P.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => CIRILLO, G.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => CESARO, G.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => GUERRERA, B.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => RICCIOTTI, R.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => MIRAGLIA DEL GIUDICE, E.
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => UTILI, R.
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => ADINOLFI, L. E.
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => RUGGIERO, G.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 15
[M] => 10
[Text] => Oct2005
[Type] => published
[Y] => 2005
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 02692813
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 22
)
[1] => Array
(
[Type] => issue
[Value] => 8
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Alimentary Pharmacology & Therapeutics
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |